Novartis
-
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
Jan 20, 2018Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangement globally. Sandoz, a... -
Novartis’s Kisqali wins FDA breakthrough therapy designation for treating breast cancer patients
Jan 3, 2018Novartis’s Kisqali has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday. The designation covers initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor... -
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
Nov 18, 2017Cancer is on the rise in Sub-Saharan Africa. Approximately 650,000 people in Africa develop cancer annually, and about 510,000 cancer deaths occur annually due to limited treatment. Novartis, the American Society for Clinical Pathology (ASCP) and... -
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
Nov 14, 2017Punjab province, with a population of 110 million, is the largest province in Pakistan, representing more than half of the country’s population. The provincial government of Punjab in Pakistan signed a Memorandum of Understanding with Novartis... -
Novartis agreed to buy AAA for $3.9 billion
Oct 30, 2017News Hour: Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.... -
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Oct 2, 2017News Hour: Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses... -
Novartis is taking aim at drug-resistant malaria
Aug 21, 2017News Hour: Novartis is taking aim at drug-resistant malaria – a growing global problem – by launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa and Asia. The... -
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention
Jun 24, 2017News Hour: Novartis announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for AMG 334 (erenumab) for the prevention of a migraine. Erenumab is an anti-CGRP monoclonal antibody developed to prevent a... -
European Medicines Agency panel recommended approving Novartis’s breast cancer drug Kisqali
Jun 23, 2017News Hour: A European Medicines Agency (EMA) panel recommended on Friday approving Novartis’s Kisqali drug, bolstering the Swiss drugmaker’s bid to challenge rival Pfizer’s Ibrance against tough-to-treat breast cancer. The EMA’s Committee for Medicinal Products for... -
Half of chronic urticaria patients are not receiving any treatment despite significant disease burden
Jun 21, 2017News Hour: Novartis announced new baseline results from a real world study of 3,733 chronic urticaria (CU) patients showing many are not receiving adequate care, with almost half (42%) not receiving any treatment at all for...
